SCHEMBL1679343

SCHEMBL1679343

C1CCCC(CNCC2CC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.56
ADH1C P00326 1/20 0.56
ADH1A P07327 1/20 0.56
ADH4 P08319 1/20 0.56
ADH7 P40394 1/20 0.56
EPHX1 P07099 3/20 0.50
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP3 P08254 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
CA9 Q16790 1/20 0.46
CYP2D6 P10635 1/20 0.45
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
CHRM2 P08172 2/20 0.42
CHRM4 P08173 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1678338 1.00 ADH1B (0.56) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1678148 1.00 ADH1B (0.56) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1678544 0.97 ADH1B (0.59) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1679033 0.97 ADH1B (0.59) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1679009 0.97 ADH1B (0.52) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1679102 0.97 ADH1B (0.59) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1679662 0.94 ADH1B (0.55) ADH1BADH1CADH1AADH4ADH7
SCHEMBL25047164 0.90 ADH1B (0.59) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1678325 0.90 ADH1B (0.52) ADH1BADH1CADH1AADH4ADH7
SCHEMBL17463610 0.87 ADH1B (0.46) ADH1BADH1CADH1AADH4ADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923573-B2 Benzene compound having 2 or more substituents DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-12 US disclosed
US-20080255111-A1 Tissue Factor Production Inhibitor SANKYO COMPANY LIMITED (JP) 2008-10-16 US disclosed
US-20080004301-A1 Benzene Compound Having 2 or More Substituents DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-01-03 US disclosed
EP-1806332-A1 BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS Daiichi Sankyo Company, Limited (JP) 2007-07-11 EP disclosed
EP-1764075-A1 TISSUE FACTOR PRODUCTION INHIBITOR Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255111-A1 Tissue Factor Production Inhibitor PTAFR, PLAT, TFPI ADH1B 2487/4885ADH1C 4567/4885ADH1A 4118/4885
US-20080004301-A1 Benzene Compound Having 2 or More Substituents NR1H2, NR1H3, NCOR2 ADH1B 998/4885ADH1C 3082/4885ADH1A 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.